Article
Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - 1 Nov 2015
Schick Ulrike, Kyula Joan, Barker Holly, Patel Radhika, Zaidi Shane, Gregory Claire, Hafsi Hind, Roulstone Victoria, Deutsch Eric, McLaughlin Martin, Harrington Kevin
Abstract excerpt
PURPOSE: Radiotherapy (RT) is used frequently in patients with melanoma, but results are suboptimal because the disease is often radioresistant. This may be due to constitutive activation of MAPK pathway signalling through mutations involving RAS/RAF. Thus, we studied whether trametinib, a potent and selective allosteric inhibitor of MEK1/2 could improve the efficacy of RT. METHODS AND MATERIALS: Clonogenic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.